Etripamil Nasal Spray for Rapid Conversion of Supraventricular Tachycardia to Sinus Rhythm

Abstract

Etripamil nasal spray rapidly terminated induced SVT with a high conversion rate. The safety and efficacy results of this study provide guidance for etripamil dose selection for future studies involving self-administration of this new intranasal calcium-channel blocker in a real-world setting for the termination of SVT. (Efficacy and Safety of Intranasal MSP-2017 [Etripamil] for the Conversion of PSVT to Sinus Rhythm [NODE-1]; NCT02296190).

Oral Anticoagulation and Antiarrhythmic Drug Therapy for Atrial Fibrillation

“…This route is both rapid and eliminates the firstpass hepatic clearance that can occur with some orally administered drugs. As reported by Stambler et al, 29 their phase II, dose-ranging, placebo-controlled trial performed during electrophysiological testing in 104 patients with previously documented SVT who were induced into SVT prior to undergoing catheter ablation provided notable efficacy and safety data. Etripamil converted 65% to 95% of patients versus 35% in the placebo group, with differences being statistically significant in the three highest active compound dose groups, using conversion within 15 minutes as the primary endpoint.…”

Update on Etripamil Nasal Spray for the At-home Treatment of Acute Paroxysmal Supraventricular Tachycardia

“…20 Dose-dependent PR prolongation was consistent with its proposed atrioventricular nodal effects, without any effect on QRS duration or QT interval. 21…”

Supraventricular tachycardia: An overview of diagnosis and management

“…16 More recently, a trial of intranasal etripamil (shortacting calcium channel blocker, currently in phase II clinical trials) terminated supraventricular arrhythmias in 65-95% of cases. 2,17 Both drug groups should be used cautiously in patients with decompensated heart failure and hypotension. Concomitant use should be avoided where possible due to the risk of significant hypotension and bradycardia.…”